Expanded recall for Franck's Compounds

Share this article:

The FDA is notifying all physicians and healthcare organizations of the recall of all sterile products sold by Franck's Compounding Pharmacy since November 2011 due to the possibility of lack of sterility.

In March 19, 2012, FDA received reports of fungal endophthalmitis in patients who were given Brilliant Blue G (BBG), supplied by Franck's Pharmacy, during eye surgeries. In April 20, 2012, FDA received reports of eye infections in patients who were given injections of Franck's drug products containing triamcinolone acetonide during eye surgery.

An active investigation by the CDC and FDA is ongoing at this time. FDA advises that any product received from Franck's since November 2011 not be used.

For more information visit http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305592.htm.

Share this article:
You must be a registered member of Clinical Advisor to post a comment.

More in Web Exclusives

COPD costs projected to reach $49B in 2020

COPD costs projected to reach $49B in 2020

Nearly 13 million U.S. adults had chronic obstructive pulmonary disease in 2011, and 24 million adults had signs of impaired lung function.

Dieting young triggers greater health complications later in life

Dieting young triggers greater health complications later in ...

In young women, dieting at a younger age predicts obesity, extreme weight control measures, and alcohol misuse.

IOM: GME funding system needs an overhaul

IOM: GME funding system needs an overhaul

Medicare should continue to support graduate medical education, contingent on value.